Association of procalcitonin, C-reaction protein and other risk factors with mortality among COVID-19 patients in Erbil city
DOI:
https://doi.org/10.15218/zjms.2025.011Keywords:
COVID-19, Procalcitonin, CRP, D-dimer, Risk factorAbstract
Background and objective: The coronavirus disease pandemic, was a serious threat to global health, which attacked the community in December 2019 without warning and had disastrous effects. Inflammatory factors are important for COVID-19 mortality. We aimed to identify potential demographic risk factors as well as the potential role of procalcitonin and other inflammatory biomarkers as indicators of severity and outcome in patients with COVID-19.
Methods: A cross-sectional prospective study that was conducted in Lalav Hospital, West Emergency Hospital and a Private clinical center in Erbil city, Iraq. The cases (106) were collected from August 2021 to November 2021. All included patients were diagnosed with COVID-19 through laboratory confirmation using real-time reverse transcriptase–polymerase chain reaction (RT-PCR).
Results: Our results showed that serum procalcitonin levels were significantly higher and positively correlated with mortality in COVID-19 patients (P = 0.005). The severity of COVID-19 and abnormal serial measurements of plasma D-dimer and serum C- reactive protein levels were found to be significantly correlated (P = 0.028 and P = 0.041, respectively). Diabetes, hypertension, and advanced age were noted as risk factors.
Conclusion: Procalcitonin may be an indicator of disease severity. Serial procalcitonin measurements and the recognition of potential risk factors are crucial for predicting the prognosis among COVID-19 patients.
Metrics
References
She J, Jiang J, Ye L, Hu L, Bai CH, Song Y. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clin Transl Med. 2020; 9(19). doi: 10.1186/s40169-020-00271-z
WHO Coronavirus (COVID-19) Dashboard. Accessed August 28, 2022. https://covid19.who.int
Pal M, Berhanu G, Desalegn C, Kandi V. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus. 2020; 12(3). doi:10.7759/cureus.7423
Zhu ZH, Lian X, Su X, Wu W, Marraro G, Zeng Y. From SARS and MERS to COVID-19: a summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res. 2020; 21(1):224. doi:10.1186/s12931-020-01479-w
Pan F, Yang L, Li Y, Liang B, Li L, Ye T, et al. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. Int J Med Sci. 2020; 17(9):1281-92. doi:10.7150/ijms.46614
Zhao W, Li H, Li J, Xu B, Xu J. The mechanism of multiple organ dysfunction syndrome in patients with COVID‐19. J Med Virol. 2022; 94(5):1886-92. doi:10.1002/jmv.27627
Wang Y, Tian H, Zhang L, Man ZH, Dandan G, Wenting W, et al. Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection, and social distancing: a cohort study in Beijing, China. BMJ Glob Health. 2020; 5(5):e002794. doi:10.1136/bmjgh-2020-002794
Samadizadeh S, Masoudi M, Rastegar M, Salimi V, Shahbaz MB, Tahamtan A. COVID-19: Why does disease severity vary among individuals? Respir Med. 2021; 180:106356. doi:10.1016/j.rmed.2021.106356
Zhao Y, Cui C, Zhang K, Jialin L, Jinfu X, Eric N, et al. COVID19: A Systematic Approach to Early Identification and Healthcare Worker Protection. Front Public Health. 2020; 8:205. doi:10.3389/fpubh.2020.00205
Milenkovic M, Hadzibegovic A, Kovac M, Jovanovic B, Stanisavljevic J, Djikic M, et al. D-dimer, CRP, PCT, and IL-6 Levels at Admission to ICU Can Predict In-Hospital Mortality in Patients with COVID-19 Pneumonia. Longevity OMAC. 2022; 2022:9. doi:10.1155/2022/8997709
Ryoo SM, Han KS, Ahn S, Tae Gun SH, Sung Yeon H, Sung Phil CH, et al. The usefulness of C-reactive protein and procalcitonin to predict prognosis in septic shock patients: A multicenter prospective registry-based observational study. Sci Rep. 2019; 9(29):6579. doi:10.1038/s41598-019-42972-7
Rowland T, Hilliard H, Barlow G. Procalcitonin: Potential Role in Diagnosis and Management. Adv Clin Chem. 2015; 68:71-86. doi:10.1016/bs.acc.2014.11.005
Vijayan AL, Vanimaya, Ravindran S, Saikant R, Lakshmi S, Kartik R, et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. J Intensive Care. 2017; 5:51. doi:10.1186/s40560-017-0246-8
Peters C, Williams K, Un EA, Little L, Saad A, Lendrum K, et al. Use of procalcitonin for antibiotic stewardship in patients with COVID-19: A quality improvement project in a district general hospital. Clin Med (Lond). 2021; 21(1):71-76. doi:10.7861/clinmed.2020-0614
Adebisi Y, Dasola N, Olushola I, Uwizeyimana TH, Olayemi A, Ukor N. The use of antibiotics in COVID-19 management: a rapid review of national treatment guidelines in 10 African countries. Trop Med Health. 2021; 49(51). doi:10.1186/s41182-021-00344-w
National Institute of Health. COVID-19 Treatment Guidelines. Accessed February 14, 2023. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
Achangwa C, Park H, Ryu S. Incubation period of wild type of SARS-CoV-2 infections by age, gender, and epidemic periods. Front Public Health. 2022; 10:905020. doi:10.3389/fpubh.2022.905020
Rashedi J, Poor BM, Asgharzadeh V, Pourostadi M, Kafil H, Vegari A, et al. Risk Factors for COVID-19. Infez Med. 2020; 28(4):469-74. PMID: 33257620
Docherty AB, Harrison EM, Green C, Hardwick H, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. Br Med J. 2020; 369(m1985). doi:10.1136/bmj.m1985
Jordan R, Adab P, Cheng K. Covid-19: risk factors for severe disease and death. Br Med J 2020; 368. doi:10.1136/bmj.m1198
Zewotir T, Dessie Z. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021; 21. doi:10.1186/s12879-021-06536-3.
Wang D, Hu B, Hu C, Xing L, Zhang J, Wang B, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020; 323. doi:10.1001/jama.2020.1585
Shepherd R, Cheung AS, Pang K, Saffery R, Novakovic B. Sexual Dimorphism in Innate Immunity: The Role of Sex Hormones and Epigenetics. Front Immunol. 2020; 11:604000. doi:10.3389/fimmu.2020.604000
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu U, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
Sun S, Martinez L, Ge Y. COVID-19 Transmission Dynamics Among Close Contacts of Index Patients With COVID-19: A Population-Based Cohort Study in Zhejiang Province, China. JAMA Intern Med. 2021; 181(10):1343-50. doi:10.1001/jamainternmed.2021.4686
Heneghan C, Spencer E. Transmission of SARs-COV-2: Updated Protocols for a series of systematic reviews. The Centre for Evidence-Based Medicine; 3. [cited 5 January 2023]; Available from: https://www.cebm.net/study/covid-19-risk-of-transmission-in-covid-19-among-close-contacts/). doi: 10.6084/m9.figshare.19229754.v3
Chen T, Dai Z, Mo P, Li X, Ma ZH, Song SH, et al. Clinical Characteristics and Outcomes of Older Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Single-Centered, Retrospective Study. J Gerontol A Biol Sci Med Sci. 2020; 75(9):1788-95. doi: 10.1093/gerona/glaa089.
Jin A, Yan B, Hua W, Feng D, Xu B, Liang L, et al. Clinical characteristics of patients diagnosed with COVID-19 in Beijing. Biosaf Health. 2020; 2(2):104-111. doi:10.1016/j.bsheal.2020.05.003
Shi L, Wang Y, Duan G, Wang Y, Yang H. Dyspnea rather than fever is a risk factor for predicting mortality in patients with COVID-19 - J Infect. 2020; 81(4). doi:10.1016/j.jinf.2020.05.013
Pullen M, Skipper C, Hullsiek K, Okafor E, Pastick K, Bangdiwala A, et al. Symptoms of COVID-19 Outpatients in the United States. Open Forum Infect Dis. 2020; 7(7). doi: 10.1093/ofid/ofaa271
Mohammed Y, Sepandi M, Taghrid M. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020; 61(3):E304-E312. doi:10.15167/2421-4248/jpmh2020.61.3.1530
Utku A, Budak G, Karabay O, Güçlü E, Okan H, Vatan A. Main symptoms in patients presenting in the COVID-19 period. Scott Med J. 2020; 65(4):127-132. doi:10.1177/0036933020949253
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu ZH, et al. Clinical course, and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
Savoia C, Volpe M, Kreutz R. Hypertension, a Moving Target in COVID-19. Circ Res. 2021; 128(7):1062-1079. doi:10.1161/CIRCRESAHA.121.318054
Lippi G, Wong J, Henry B. Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020; 130. doi:10.20452/pamw.15272
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?Lancet Respir Med. 2020; 8(4):e21. doi:10.1016/S2213-2600(20)30116-8
Rao SH, Lau A, So H. Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits. Diabetes Care. 2020; 43(7):1416-1426. doi:10.2337/dc20-0643
Zavareh M, Bayani M, Shokri M, Ebrahimpour S, Babazadeh A, Mehraeen R, et al. C-Reactive Protein as a Prognostic Indicator in COVID-19 Patients. Interdiscip Perspect Infect Dis. 2021;.2021:5557582. doi: 10.1155/2021/5557582.
Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020; 127:104370. doi:10.1016/j.jcv.2020.104370
Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection.
Clin Chem Lab Med. 2020; 58(7):1131-1134. doi:10.1515/cclm-2020-0198
Vanhomwegen C, Veliziotis I, Malinverni S, Konopnicki D, Dechamps PH, Claus M, et al. Procalcitonin accurately predicts mortality but not bacterial infection in COVID-19 patients admitted to intensive care unit. Ir J Med Sci. 2021; 190(4): 1649–1652. doi:10.1007/s11845-020-02485-z
Tan L, Kang X, Ji X, Li G, Wang Q, Li Y, et al. Validation of Predictors of Disease Severity and Outcomes in COVID-19 Patients: A Descriptive and Retrospective Study. Med. 2020; 1(1):128-38.e3. doi:10.1016/j.medj.2020.05.002
Zhou Y, Teng X, Han M, Shi J, Li X, Zhang X, et al. The value of PCT, IL-6, and CRP in the early diagnosis and evaluation of COVID-19. Eur Rev Med Pharmacol Sci. 2021; 25(2):1097-100. doi:10.26355/eurrev_202101_24680
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Tara Srood Suad , Chato Ali Taher (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).
